The combination of domvanalimab (targeting TIGIT) with Zimberelimab (targeting PD-1) has been shown to enhance T-cell responses in preclinical models of GBM, resulting in reduced tumor growth and improved survival [163]. This evidence concerns the gene PDCD1 and neoplasm.